Spots Global Cancer Trial Database for A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
Official Title: An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
Study ID: NCT03512353
Conditions
Study Description
Brief Summary: The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.
Detailed Description: This is a phase 2, multicenter, open-label study in adults with RRMM in US community oncology centers. Adults with 1-3 prior lines of therapy at study entry are eligible to be screened for participation. Patients refractory to their last line of treatment are eligible to participate as long as their last line of treatment did not include a proteasome inhibitor (PI). The study will consist of a screening period of up to 28 days for bone marrow assessments and up to 21 days for all other assessments, up to 12 cycles of treatment, and a 30-day safety follow-up period following the last dose of study drug.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Palm Springs, California, United States
Research Site, Riverside, California, United States
Research Site, Glenwood Springs, Colorado, United States
Research Site, Boynton Beach, Florida, United States
Research Site, Orange City, Florida, United States
Research Site, Pensacola, Florida, United States
Research Site, Honolulu, Hawaii, United States
Research Site, River Forest, Illinois, United States
Research Site, Tinley Park, Illinois, United States
Research Site, Indianapolis, Indiana, United States
Research Site, Paducah, Kentucky, United States
Research Site, Bethesda, Maryland, United States
Research Site, Midland, Michigan, United States
Research Site, Jackson, Mississippi, United States
Research Site, Lincoln, Nebraska, United States
Research Site, Florham Park, New Jersey, United States
Research Site, Charlotte, North Carolina, United States
Research Site, Charlotte, North Carolina, United States
Research Site, Hendersonville, North Carolina, United States
Research Site, Pinehurst, North Carolina, United States
Research Site, Winston-Salem, North Carolina, United States
Research Site, Zanesville, Ohio, United States
Research Site, Charleston, South Carolina, United States
Research Site, Rock Hill, South Carolina, United States
Research Site, Corpus Christi, Texas, United States
Research Site, Fort Worth, Texas, United States
Research Site, Houston, Texas, United States
Research Site, Houston, Texas, United States
Research Site, Ogden, Utah, United States
Research Site, Fredericksburg, Virginia, United States
Research Site, Yakima, Washington, United States
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
